secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001193125-24-250223
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista secures up to $179M synthetic royalty financing with DRI for sebetralstat launch
--------------------------------------------------------------------------------

- Upfront payment of $100M; potential total up to $179M including $22M optional approval payment and $57M sales milestone.
- Tiered royalties: 5% on net sales up to $500M, 1.1% on $500M-$750M, 0.25% above $750M; rate increases if optional payment taken.
- Additional $22M optional if US approval by Sep 30, 2025; PDUFA date June 17, 2025 for sebetralstat (oral HAE therapy).
- DRI expressed non-binding interest in up to $5M private placement of KalVista common stock.
- Royalty financing non-dilutive; proceeds to fund commercial launch of sebetralstat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524250223/0001193125-24-250223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524250223/d904891d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-250223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer